Trisalus Life Sciences Inc Revenue Growth Rates (TLSI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Trisalus Life Sciences Inc   (NASDAQ: TLSI)
 

TLSI's Revenue Growth by Quarter and Year

Trisalus Life Sciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TLSI Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 11.41
1st Quarter March 8.67
FY 20.08





TLSI Revenue second quarter 2026 Y/Y Growth Comment
Trisalus Life Sciences Inc reported Revenue growth of 9.58% year on year in the second quarter 2026, to $ 11.41 millions, this is lower than Trisalus Life Sciences Inc 's recent average Revenue rise of 48.1%.

Looking into second quarter 2026 results within Medical Equipment & Supplies industry 94 other companies have achieved higher Revenue growth. While Trisalus Life Sciences Inc ' s Revenue increase of 9.58% ranks overall at the positon no. 1768 in the second quarter 2026.


TLSI Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 76.96 % 42.66 % 77.09 %
3rd Quarter September - 45.03 % 41.62 % 32.4 %
2nd Quarter June 9.58 % 41.44 % 59.65 % -
1st Quarter March 0 % 34.21 % 116.78 % -
FY   - 50.63 % 58.54 % -

Financial Statements
Trisalus Life Sciences Inc 's second quarter 2026 Revenue $ 11.41 millions TLSI's Income Statement
Trisalus Life Sciences Inc 's second quarter 2025 Revenue $ 10.41 millions Quarterly TLSI's Income Statement


TLSI Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 35.46 % 11.02 % 10.21 %
3rd Quarter September - 2.4 % -0.14 % 12.58 %
2nd Quarter June 31.57 % 20.07 % 13.93 % 54.7 %
1st Quarter March -39.96 % 6.25 % 12.94 % -7.74 %
FY (Year on Year)   - 50.63 % 58.54 % -


Back to TLSI Growth rate Comparisons >> Back to TLSI Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #95
Healthcare Sector #280
Overall #1768

Revenue Y/Y Growth Statistics
High Average Low
116.39 % 48.1 % -0.03 %
(Dec 31 2025)   (Mar 31 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #95
Healthcare Sector #280
Overall #1768
Revenue Y/Y Growth Statistics
High Average Low
116.39 % 48.1 % -0.03 %
(Dec 31 2025)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Trisalus Life Sciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
54.56 % 9.71 % -39.98 %
(Jun 30 2023)  


TLSI's II. Quarter Q/Q Revenue Comment
Trisalus Life Sciences Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 31.57%, to $ 11.41 millions, from $8.67 millions in the first quarter.
TLSI is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Trisalus Life Sciences Inc 's Revenue growth quarter on quarter, overall rank is 353.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #19
Healthcare Sector #81
Overall #353
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #19
Healthcare Sector #81
Overall #353
Revenue Q/Q Growth Statistics
High Average Low
54.56 % 9.71 % -39.98 %
(Jun 30 2023)  


TLSI's II. Quarter Q/Q Revenue Comment
Trisalus Life Sciences Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 31.57%, to $ 11.41 millions, from $8.67 millions in the first quarter.
TLSI is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Trisalus Life Sciences Inc 's Revenue growth quarter on quarter, overall rank is 353.


Trisalus Life Sciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 45.18 $ 44.18 $ 44.19 $ 37.91 $ 34.59
Y / Y Revenue Growth (TTM) 30.61 % 40.07 % 50.66 % 40.98 % 39.84 %
Year on Year Revenue Growth Overall Ranking # 1625 # 1125 # 1267 # 1255 # 1051
Seqeuential Revenue Change (TTM) 2.25 % -0.01 % 16.57 % 9.58 % 9.66 %
Seq. Revenue Growth (TTM) Overall Ranking # 1745 # 1653 # 2880 # 1475 # 1353


Cumulative Revenue growth Comment
Assuming the Trisalus Life Sciences Inc 's fiscal year would have ended in Jun 30 2026, Trisalus Life Sciences Inc would have reprted above average annual Revenue rise of 30.61% year on year, of $ 45 millions.
This marks a slow-down of the companys growth trends and from the 40.07% increase in Mar 31 2026.

In the Healthcare sector 263 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1125 to 1625.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 105
Healthcare Sector # 264
Overall # 1625

Revenue TTM Y/Y Growth Statistics
High Average Low
50.66 %
 22.58 %
8.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 279
S&P 500 # 1745
Cumulative Revenue growth Comment
Assuming the Trisalus Life Sciences Inc 's fiscal year would have ended in Jun 30 2026, Trisalus Life Sciences Inc would have reprted above average annual Revenue rise of 30.61% year on year, of $ 45 millions.
This marks a slow-down of the companys growth trends and from the 40.07% increase in Mar 31 2026.

In the Healthcare sector 263 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1125 to 1625.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 105
Healthcare Sector # 264
Overall # 1625

Revenue TTM Y/Y Growth Statistics
High Average Low
50.66 %
22.58 %
8.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 279
S&P 500 # 1745




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TLSI's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Regeneron Pharmaceuticals Inc 16.73%$ 16.735 millions
Invo Fertility Inc 16.73%$ 16.732 millions
Pro dex Inc 16.65%$ 16.646 millions
Royalty Pharma Plc16.50%$ 16.499 millions
Acadia Pharmaceuticals Inc 16.40%$ 16.402 millions
Harvard Bioscience Inc 16.35%$ 16.352 millions
Alpha Pro Tech Ltd 15.76%$ 15.765 millions
Armata Pharmaceuticals Inc 15.72%$ 15.722 millions
Lifeward ltd 15.71%$ 15.706 millions
Novocure Limited15.60%$ 15.603 millions
Ufp Technologies Inc 15.56%$ 15.558 millions
Orthopediatrics Corp15.55%$ 15.551 millions
Jazz Pharmaceuticals Plc15.55%$ 15.548 millions
Alphatec Holdings Inc 15.35%$ 15.349 millions
Penumbra Inc14.90%$ 14.904 millions
Rockwell Medical inc 14.69%$ 14.687 millions
Sbc Medical Group Holdings Incorporated14.36%$ 14.363 millions
Nuwellis Inc 14.14%$ 14.145 millions
West Pharmaceutical Services Inc 13.89%$ 13.892 millions
Edwards Lifesciences Corporation13.66%$ 13.657 millions
Indivior Pharmaceuticals Inc 13.58%$ 13.576 millions
Talkspace Inc 13.56%$ 13.556 millions
Atricure Inc 13.38%$ 13.376 millions
Dexcom Inc 13.11%$ 13.105 millions
Sanara Medtech Inc 13.03%$ 13.028 millions
Bausch Health Companies Inc 12.73%$ 12.727 millions
Vertex Pharmaceuticals Inc12.45%$ 12.453 millions
Genedx Holdings Corp 12.30%$ 12.304 millions
Profound Medical Corp 12.30%$ 12.302 millions
Xenetic Biosciences Inc 11.99%$ 11.986 millions


About Trisalus Life Sciences Inc Revenue Growth Rates (TLSI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Trisalus Life Sciences Inc (CIK 1826667).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-054275
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Trisalus Life Sciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.